Oil Price Surge Drives API Costs Higher as Vitamins Lead Gains

The recent surge in global crude oil prices, triggered by tightening supply and escalating geopolitical tensions in the Middle East, is now spreading beyond energy and petrochemicals into the pharmaceutical supply chain, opening a potential pricing recovery window for active pharmaceutical ingredients (APIs).

Following the escalation of regional conflict in late February 2026 and the closure of the Strait of Hormuz, a critical artery for global energy transport, U.S. benchmark West Texas Intermediate (WTI) crude briefly surged above $100 per barrel. Rising feedstock and freight costs have since moved downstream through the chemical value chain, with APIs — an industry that has undergone years of capacity rationalization — beginning to feel the impact.

The key question for markets is how quickly higher oil prices can be passed on to pharmaceutical raw materials, which products are already seeing price increases, and why the impact remains uneven across segments.

Crude Oil Surge Pushes Cost Pressure Downstream

The current wave of price pressure began with the disruption of one of the world's most important energy chokepoints.

In late February 2026, geopolitical tensions in the Middle East escalated sharply, forcing the closure of the Strait of Hormuz. The waterway typically handles around 20 million barrels per day of crude oil and petroleum product shipments globally. Its closure created an estimated supply shortfall of around 5 million barrels per day.

As a result, the average WTI crude price in March jumped 41% month-on-month, reaching an intraday high of $102.88 per barrel.

In its latest report, Guosen Securities said international oil prices could continue accelerating in April, with short-term prices potentially exceeding $120 per barrel. The brokerage raised its 2026 average Brent and WTI price forecasts to $80–$90 per barrel.

The sharp rise in crude prices has triggered a chain reaction across the petrochemical industry. Data showed the petroleum and chemical industry prosperity index rose 2.49 percentage points month-on-month in March, though performance diverged sharply across the value chain.

Upstream oil and gas exploration and fuel processing sectors posted strong rebounds, while midstream and downstream segments such as chemical raw materials and chemical products manufacturing saw declines due to weak end-market demand and incomplete cost pass-through.

This suggests cost pressure from higher crude prices is accumulating in downstream sectors, including pharmaceutical intermediates and APIs, which sit near the end of the transmission chain.

Vitamins A and E Prices Nearly Double as Producers Halt Quotations

Vitamins have been among the first pharmaceutical-related products to reflect rising cost pressures.

According to market data, the price of Vitamin A rose from 60.50 yuan ($8.31) per kilogram on Feb. 27 to 116.50 yuan per kilogram on Apr. 17, an increase of around 93% in just over one month.

Vitamin E prices climbed from 57.50 yuan per kilogram to 116.50 yuan per kilogram over the same period, nearly doubling.

Kaiyuan Securities said the global vitamin market is mainly supplied by companies including DSM-Firmenich, BASF and Chinese producers. Against a backdrop of rising crude prices, major suppliers have collectively suspended quotations and contract signings, pushing Vitamin A and E prices sharply higher.

China Post Securities noted that vitamin APIs had previously been trading near historical lows. Simultaneous increases in upstream chemical feedstock prices and oil shipping costs have strengthened industry willingness to curb production and raise prices.

Vitamins are mainly used as feed additives and account for only a small portion of total feed costs, making downstream customers relatively insensitive to price increases. This has enabled smoother price transmission and greater upside potential.

Capital markets reacted quickly. Shares of Chinese vitamin producer NHU have risen nearly 40% year-to-date.

In a March investor briefing, NHU said it was stabilizing supply and controlling costs through strategic procurement, centralized purchasing and long-term supply agreements. The company added that supply of core raw materials remained stable and recent market prices for major products had increased.

A research note from CSC Financial said NHU's new production capacity coming online in 2026, combined with supply disruptions overseas, could drive both higher volume and pricing for methionine, supporting profit growth throughout the year.

Sartans Show Early Signs of a Turnaround While Steroid APIs Remain Stable

Beyond vitamins, sartan-based APIs are emerging as another area of potential price gains.

Shares of Chinese API maker Menovo Pharmaceutical have surged 173.02% so far this year, the strongest performance in China's listed API sector.

On Apr. 21, company representatives told local media that intermediates and basic raw materials used in API production are mainly sourced domestically in China and have begun showing price increases due to the indirect effects of higher oil prices.

More importantly, supply-side dynamics are shifting.

At an investor conference on Mar. 20, Menovo said major manufacturers of sartan APIs were no longer operating in an oversupply environment. Upstream materials such as bromine have already risen in price, and some sartan product prices are beginning to turn upward.

The company added that resistance to 'reasonable price increases' appears limited.

The logic reflects broader industry trends. The peak of API capacity expansion during the pandemic has passed, and the cycle for major new capacity additions is largely over. Meanwhile, demand for chronic disease medications continues to rise.

This is gradually shifting supply-demand dynamics from severe imbalance toward a new equilibrium.

Steroid APIs See Limited Impact Despite Sector Rally

Not all API segments are benefiting from the latest round of cost inflation.

Shares of Chinese pharmaceutical producer Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited have gained 54% year-to-date. However, in a recent risk disclosure filing, the company said prices for steroid hormone APIs have remained broadly stable and currently have no material impact on operating performance.

The divergence highlights that cost pass-through from crude oil is not universal.

Whether API producers can successfully raise prices depends largely on supply-demand conditions, downstream price sensitivity, and the extent of capacity rationalization in each segment.

Industry Nears an Inflection Point as Capacity Rationalization Meets Rising Costs

Several brokerages believe the API sector is entering a window where multiple supportive factors are converging.

Kaiyuan Securities said China's API industry has undergone a prolonged period of supply-side rationalization. As geopolitical tensions continue to push up crude and upstream chemical feedstock prices, the sector may be entering a new price upcycle.

The brokerage recommends focusing on companies and product categories where capacity has been thoroughly cleared and price increases are more likely.

In specific categories, the antibiotic supply chain has already begun stabilizing and recovering.

Prices for 6-APA and industrial-grade penicillin salt have rebounded from lows, while downstream APIs such as amoxicillin and ampicillin are also on an upward trajectory.

In animal health APIs, average prices for florfenicol have fallen sharply from previous highs into the 100–200 yuan per kilogram range. With some producers posting consecutive losses, industry consolidation is accelerating, and prices may see cyclical recovery in 2026.

At an Apr. 20 investor call, Chinese pharmaceutical company Apeloa Pharmaceutical said basic raw material prices rose 10% to 15% in the early stages of the latest international disruption.

The company said it moved quickly to negotiate with customers and had largely absorbed the impact through product price increases, with some key products performing even better.

Apeloa added that continued capacity cuts in China, fewer new entrants and more rational competition could support a gradual recovery in API prices, with industry conditions expected to improve in the second and third quarters.

Structural Opportunities Outweigh Broad-Based Gains

Overall, the impact of rising crude prices on the API sector is becoming increasingly visible, but the transmission process has three defining characteristics.

First, price gains are highly selective.

Products such as vitamins, where downstream demand is less price-sensitive and industry concentration is high, are seeing smoother price increases. Other categories such as steroid hormones remain relatively stable.

Second, there is a lag effect.

The transmission of cost pressure from crude oil to base chemicals, pharmaceutical intermediates and eventually APIs involves multiple stages of cost absorption and pricing negotiations.

Third, supply-side dynamics are critical.

Products with more complete capacity rationalization face less resistance to price increases, while oversupplied segments may struggle to pass on higher costs.

For investors and industry observers, the more rational approach may be to focus less on the broad narrative that 'higher oil prices benefit the entire API sector' and more on the specific supply-demand balance, competitive structure and downstream pricing sensitivity of individual product categories.